Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EMBARK

- PMLiVE

Astellas taps Lilly for comms chief

Jeffrey Winton appointed first chief communications officer

- PMLiVE

Astellas wins NICE backing for Xtandi in prostate cancer

England’s health guidance body says drug can be used in advanced cases of the disease

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

- PMLiVE

Dendreon’s cancer vaccine wins EU approval

Provenge approved for use in prostate cancer three years after US recommendation

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy fails prostate cancer trial

Unable to improve overall survival in phase III

- PMLiVE

Lundbeck still ‘appalled’ by EC’s €94m anti-competition fine

Will appeal, but doesn't expect a quick decision

- PMLiVE

Astellas poaches new oncology head from Takeda

Claire Thom is named senior VP of global oncology development

- PMLiVE

European Commission hails progress on paediatric medicines

Says improvements made on both safety and research in Europe

- PMLiVE

Astellas wins EU approval for prostate cancer drug Xtandi

Will compete with J&J’s big-selling Zytiga

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

- PMLiVE

FDA turns down tivozanib for kidney cancer

Agency describes data provided by Aveo Oncology and Astellas as "uninterpretable"

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links